None listed
Conditions
Brief summary
The study will investigate whether pretreatment with the drug Rosiglitazone attenuates the increase in activity of muscle 11betaHSD-1 following treatment with the potent steroid dexamethasone. Dexamethasone is well known to cause an increase in blood glucose levels in people with type 2 diabetes and we are investigating a possible mechanism for this.
Interventions
Rosiglitazone 8mg per day orally for 24 days.
Dexamethasone 4mg per day for 4 days orally, commencing on Day 18 of the Rosiglitazone treatment
Sponsors
Dr Warrick Inder
Study design
Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Open (masking not used)
Eligibility
Sex/Gender
All
Age
30 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
Type 2 diabetes mellitus by current WHO criteriaTreated with diet alone, metformin, sulphonylureas and/or acarboseGood understanding of written and spoken English
Exclusion criteria
Treatment with insulin or thiazolidinedionesSignificant chronic renal impairment, estimated glomerular filtration rate (eGFR) <40ml/min and/or serum creatinine >200umol/LLiver disease as defined by alanine transaminase (ALT) >2x upper limit of laboratory normal rangeUncontrolled diabetes as defined by Haemoglobin A1c (HbA1c) >10%Unstable heart disease as defined by myocardial infarction within 3 months, class III/IV angina pectoris or congestive heart failure.Active infection of any kind.
Outcome results
None listed